• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于多变量免疫反应终点的疫苗方案筛选中特征选择的方法

Methods for Feature Selection in Down-Selection of Vaccine Regimens Based on Multivariate Immune Response Endpoints.

作者信息

Huang Ying, Tarkhan Aliasghar

机构信息

Fred Hutchinson Cancer Research Center, Seattle, WA 98109 USA.

Department of Biostatistics, University of Washington, Seattle, WA 98109 USA.

出版信息

Stat Biosci. 2020;12(3):353-375. doi: 10.1007/s12561-020-09275-2. Epub 2020 Apr 15.

DOI:10.1007/s12561-020-09275-2
PMID:32421096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7224061/
Abstract

In clinical trials, it is often of interest to compare and order several candidate regimens based on multiple endpoints. For example, in HIV vaccine development, immune response profiles induced by vaccination are key for selecting vaccine regimens to advance to efficacy evaluation. Motivated by the need to rank and choose a few vaccine regimens based on their immunogenicity in phase I trials, Huang et al. (Biostatistics 18(2):230-243, 2017) proposed a ranking/filtering/selection algorithm that down-selects vaccine regimens to satisfy the superiority and non-redundancy criteria, based on multiple immune response endpoints. In practice, many candidate immune response endpoints can be correlated with each other. An important question that remains to be addressed is how to choose a parsimonious set of the available immune response endpoints to effectively compare regimens. In this paper, we propose novel algorithms for selecting immune response endpoints to be used in regimen down-selection, based on importance weights assigned to individual endpoints and their correlation structure. We show through extensive simulation studies that pre-selection of endpoints can substantially improve performance of the subsequent regimen down-selection process. The application of the proposed method is demonstrated using a real example in HIV vaccine research, although the methods are also applicable in general to clinical research for dimension reduction when comparing regimens based on multiple candidate endpoints.

摘要

在临床试验中,基于多个终点比较并排序几种候选治疗方案通常很有意义。例如,在HIV疫苗研发中,疫苗接种诱导的免疫反应谱是选择推进到疗效评估阶段的疫苗方案的关键。受在I期试验中根据免疫原性对几种疫苗方案进行排名和选择的需求驱动,Huang等人(《生物统计学》18(2):230 - 243,2017年)提出了一种排名/筛选/选择算法,该算法基于多个免疫反应终点向下选择疫苗方案,以满足优越性和非冗余标准。在实际中,许多候选免疫反应终点可能相互关联。一个有待解决的重要问题是如何选择一组简洁的可用免疫反应终点,以有效地比较治疗方案。在本文中,我们基于赋予各个终点的重要性权重及其相关结构,提出了用于选择在方案向下选择中使用的免疫反应终点的新算法。我们通过广泛的模拟研究表明,终点的预选可以显著提高后续方案向下选择过程的性能。使用HIV疫苗研究中的一个实际例子展示了所提出方法的应用,尽管这些方法一般也适用于基于多个候选终点比较治疗方案时进行降维的临床研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/5730579e6a06/12561_2020_9275_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/f2b0ee2a2758/12561_2020_9275_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/f5eafaee24c5/12561_2020_9275_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/469a74bd28a0/12561_2020_9275_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/1e7fac8bde08/12561_2020_9275_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/d5ad41085c88/12561_2020_9275_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/5730579e6a06/12561_2020_9275_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/f2b0ee2a2758/12561_2020_9275_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/f5eafaee24c5/12561_2020_9275_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/469a74bd28a0/12561_2020_9275_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/1e7fac8bde08/12561_2020_9275_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/d5ad41085c88/12561_2020_9275_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/64ab/7224061/5730579e6a06/12561_2020_9275_Fig6_HTML.jpg

相似文献

1
Methods for Feature Selection in Down-Selection of Vaccine Regimens Based on Multivariate Immune Response Endpoints.基于多变量免疫反应终点的疫苗方案筛选中特征选择的方法
Stat Biosci. 2020;12(3):353-375. doi: 10.1007/s12561-020-09275-2. Epub 2020 Apr 15.
2
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.基于多个终点进行治疗方案筛选的统计方法及其在HIV疫苗试验中的应用
Biostatistics. 2017 Apr 1;18(2):230-243. doi: 10.1093/biostatistics/kxw043.
3
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.用于在疗效试验中同时进行测试的HIV疫苗候选株的选择。
Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29.
4
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).缩短马赛克 HIV-1 疫苗接种方案的比较:一项随机、双盲、安慰剂对照的 1 期临床试验(IPCAVD010/HPX1002)和恒河猴(NHP 17-22)的临床前研究。
Lancet HIV. 2020 Jun;7(6):e410-e421. doi: 10.1016/S2352-3018(20)30001-1. Epub 2020 Feb 17.
5
Methods for comparing durability of immune responses between vaccine regimens in early-phase trials.早期临床试验中比较疫苗方案免疫应答持久性的方法。
Stat Methods Med Res. 2020 Jan;29(1):78-93. doi: 10.1177/0962280218820881. Epub 2019 Jan 9.
6
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).在一项多中心、随机、双盲、安慰剂对照的 1/2a 期临床试验(APPROACH)和恒河猴(NHP 13-19)中评估马赛克 HIV-1 疫苗。
Lancet. 2018 Jul 21;392(10143):232-243. doi: 10.1016/S0140-6736(18)31364-3. Epub 2018 Jul 6.
7
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.一项用于评估多种HIV疫苗方案的疫苗效力和免疫相关性的2b期序贯试验设计
Stat Commun Infect Dis. 2011 Oct;3(1). doi: 10.2202/1948-4690.1037.
8
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
9
Analyzing cellular immunogenicity in vaccine clinical trials: a new statistical method including non-specific responses for accurate estimation of vaccine effect.分析疫苗临床试验中的细胞免疫原性:一种新的统计方法,包括非特异性反应,可准确估计疫苗效果。
J Immunol Methods. 2020 Feb;477:112711. doi: 10.1016/j.jim.2019.112711. Epub 2019 Dec 3.
10
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.通过标准、加速或缩短免疫程序接种的寨卡病毒纯化灭活疫苗的安全性和免疫原性:一项单中心、双盲、序贯组、随机、安慰剂对照的1期试验
Lancet Infect Dis. 2020 Sep;20(9):1061-1070. doi: 10.1016/S1473-3099(20)30085-2. Epub 2020 May 6.

引用本文的文献

1
Introduction to Special Issue on 'Statistical Methods for HIV/AIDS Research'.“艾滋病研究的统计方法”特刊引言
Stat Biosci. 2020;12(3):263-266. doi: 10.1007/s12561-020-09296-x. Epub 2020 Oct 19.

本文引用的文献

1
Inference on treatment effect modification by biomarker response in a three-phase sampling design.在三阶段抽样设计中通过生物标志物反应推断治疗效果的修饰作用。
Biostatistics. 2020 Jul 1;21(3):545-560. doi: 10.1093/biostatistics/kxy074.
2
Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.通过重新校准特定类型疫苗效力的基线协变量和中间反应终点效应修饰因子来预测新环境中的总体疫苗效力。
Epidemiol Methods. 2016 Dec;5(1):93-112. doi: 10.1515/em-2015-0007. Epub 2016 Jan 23.
3
Statistical methods for down-selection of treatment regimens based on multiple endpoints, with application to HIV vaccine trials.
基于多个终点进行治疗方案筛选的统计方法及其在HIV疫苗试验中的应用
Biostatistics. 2017 Apr 1;18(2):230-243. doi: 10.1093/biostatistics/kxw043.
4
Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.用于在疗效试验中同时进行测试的HIV疫苗候选株的选择。
Curr Opin Virol. 2016 Apr;17:57-65. doi: 10.1016/j.coviro.2016.01.007. Epub 2016 Jan 29.
5
Design and estimation for evaluating principal surrogate markers in vaccine trials.疫苗试验中评估主要替代标志物的设计与估计
Biometrics. 2013 Jun;69(2):301-9. doi: 10.1111/biom.12014. Epub 2013 Feb 14.
6
A Sequential Phase 2b Trial Design for Evaluating Vaccine Efficacy and Immune Correlates for Multiple HIV Vaccine Regimens.一项用于评估多种HIV疫苗方案的疫苗效力和免疫相关性的2b期序贯试验设计
Stat Commun Infect Dis. 2011 Oct;3(1). doi: 10.2202/1948-4690.1037.
7
Immune-correlates analysis of an HIV-1 vaccine efficacy trial.HIV-1 疫苗功效试验的免疫相关性分析。
N Engl J Med. 2012 Apr 5;366(14):1275-86. doi: 10.1056/NEJMoa1113425.
8
Comparing biomarkers as principal surrogate endpoints.比较生物标志物作为主要替代终点。
Biometrics. 2011 Dec;67(4):1442-51. doi: 10.1111/j.1541-0420.2011.01603.x. Epub 2011 Apr 22.
9
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.在泰国使用ALVAC和AIDSVAX疫苗预防HIV-1感染。
N Engl J Med. 2009 Dec 3;361(23):2209-20. doi: 10.1056/NEJMoa0908492. Epub 2009 Oct 20.
10
Evaluating candidate principal surrogate endpoints.评估候选主要替代终点。
Biometrics. 2008 Dec;64(4):1146-54. doi: 10.1111/j.1541-0420.2008.01014.x. Epub 2008 Mar 24.